Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...
Jonathon Brown | August 31, 2023 |

XPhyto: Is Mescaline the Next Big Mood-Modifying Medicine?

It has the potential to be the next frontier in the psychedelics renaissance, and it represents an unprecedented opportunity to innovate a notable advancement in mental health therapy. In anecdotal studies, mescaline has shown promise in treating depression, anxiety, PTSD,...
Marc Davis | April 6, 2021 |

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

The Company That’s Delivering Safe, Evidence-Based Psychedelic-Assisted Psychotherapies

(Click image to play podcast) Stockhouse investors who are dialed into the not-only nascent but now, pardon the pun, mushrooming psychedelics sector are likely familiar with a mental health and wellness company “centred on developing and supporting the safe, ev...
Dave Jackson | October 8, 2020 |

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

When Stockhouse Editorial last caught up with Cybin Inc. ( NEO.CYBN , NYSE: CYBIN , Forum ) back in October, our audience learned about a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discover...
Dave Jackson | January 31, 2022 |

The Psychedelic Opportunity You Need to Know About

When Stockhouse Editorial last caught up with Toronto-based CYBIN Inc. ( N.CYBN , OTC: CYBN , Forum ) back in September 2020 , the psychedelic life sciences company was just going public…and to much fanfare. Cybin is a life sciences company that views psychedelic subst...
Dave Jackson | October 19, 2021 |

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...
Streetwise Reports | September 27, 2019 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |

Psyence Group: natural psychedelics for mental health and wellbeing

Our next company works to help people with a focus on natural psychedelics. Psyence Group uses natural psilocybin products to heal psychological trauma and to calm the mind during someone’s last stage of life while in palliative care. Here with us toda...
Brieanna McCutcheon | March 2, 2023 |

Numinus Wellness: The mental health business is estimated to grow to $530 billion by 2030

Numinus Wellness is in the business of psychedelic medicine but, more importantly, the mental health business. The mental health business is a sector that will be worth an estimated $530 billion dollars by the year 2030. Numinus has already seen more than a 618% ...
Brieanna McCutcheon | January 30, 2023 |
1 2 3 4 5 6 7 8 9 10 ...